Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 21, 2008. The report details a specific corporate action regarding the company's share buyback program authorized by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share repurchases.
- Shares Purchased: 3,250,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,216.8684 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.04% of total voting rights).
- Shares in Issue: 5,245,812,997 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 3,250,000 shares purchased on July 21, 2008. This transaction increased the proportion of shares held in Treasury to 9.04% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding the share buyback.
Key Facts for Investor Verification
- Verify the total cost of the buyback transaction (3,250,000 shares at 1,216.8684 pence).
- Confirm the updated total voting rights denominator (5,245,812,997 shares) for disclosure threshold calculations.
- Note that the purchased shares were cancelled rather than held indefinitely in treasury, though the company retains a significant treasury holding from prior purchases.